3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase 1
7
Phase 1/2
3
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
24
Carcinoma, Renal Cell
16
Stomach Neoplasms
9
Lung Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Carcinoma, Hepatocellular
6
Kidney Neoplasms
5
Brain Neoplasms
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Mesothelioma
4
Adenocarcinoma Of Esophagus
4
Skin Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Anus Neoplasms
3
Various Advanced Cancer
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Mesothelioma, Malignant
2
Liver Neoplasms
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma
2
Anal Canal Carcinoma
2
Adenocarcinoma
2
von Hippel-Lindau Disease
1
Interventions
Dexamethasone
169
Bortezomib
92
Lenalidomide
85
daratumumab
44
Thalidomide
44
pomalidomide
43
Melphalan
40
Cyclophosphamide
33
carfilzomib
29
Calcium Dobesilate
27
Prednisone
19
Doxorubicin
16
elotuzumab
14
isatuximab
12
Filgrastim
12
ixazomib
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
belantamab mafodotin
9
Granulocyte Colony-Stimulating Factor
9
Zoledronic Acid
8
selinexor
7
dexamethasone acetate
7
Epoetin Alfa
7
Etoposide
6
fludarabine
5
Cisplatin
5
Carmustine
5
iberdomide
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Multiple Myeloma
×
Nivolumab
×
Clear all
NCT02726581
2023-03-27
CheckMate 602
Bristol-Myers Squibb
Phase 3
Completed
170 enrolled
16 charts